IL141877A0 - Pharmaceutical compositions containing alpha4 integrin antagonists - Google Patents

Pharmaceutical compositions containing alpha4 integrin antagonists

Info

Publication number
IL141877A0
IL141877A0 IL14187799A IL14187799A IL141877A0 IL 141877 A0 IL141877 A0 IL 141877A0 IL 14187799 A IL14187799 A IL 14187799A IL 14187799 A IL14187799 A IL 14187799A IL 141877 A0 IL141877 A0 IL 141877A0
Authority
IL
Israel
Prior art keywords
alpha4 integrin
pharmaceutical compositions
compositions containing
integrin antagonists
multiple myeloma
Prior art date
Application number
IL14187799A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of IL141877A0 publication Critical patent/IL141877A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
IL14187799A 1998-09-14 1999-09-13 Pharmaceutical compositions containing alpha4 integrin antagonists IL141877A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10018298P 1998-09-14 1998-09-14
PCT/US1999/021170 WO2000015247A2 (en) 1998-09-14 1999-09-13 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

Publications (1)

Publication Number Publication Date
IL141877A0 true IL141877A0 (en) 2002-03-10

Family

ID=22278506

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14187799A IL141877A0 (en) 1998-09-14 1999-09-13 Pharmaceutical compositions containing alpha4 integrin antagonists
IL197686A IL197686A0 (en) 1998-09-14 2009-03-19 Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL197686A IL197686A0 (en) 1998-09-14 2009-03-19 Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith

Country Status (29)

Country Link
US (1) US7211252B2 (es)
EP (2) EP1113810B1 (es)
JP (3) JP2002524529A (es)
KR (1) KR100628818B1 (es)
CN (1) CN1236815C (es)
AT (1) ATE418999T1 (es)
AU (1) AU757873B2 (es)
BR (1) BR9913705A (es)
CA (1) CA2343579C (es)
CY (1) CY1109413T1 (es)
CZ (1) CZ302997B6 (es)
DE (1) DE69940206D1 (es)
DK (1) DK1113810T3 (es)
EA (1) EA004270B1 (es)
EE (1) EE05558B1 (es)
ES (1) ES2319831T3 (es)
HK (1) HK1038313A1 (es)
HU (1) HU229038B1 (es)
IL (2) IL141877A0 (es)
IS (1) IS2631B (es)
NO (2) NO327855B1 (es)
NZ (1) NZ511062A (es)
PL (1) PL203114B1 (es)
PT (1) PT1113810E (es)
SI (1) SI1113810T1 (es)
SK (1) SK287601B6 (es)
TR (1) TR200100734T2 (es)
WO (1) WO2000015247A2 (es)
ZA (1) ZA200102032B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
WO2001019396A1 (en) * 1999-09-14 2001-03-22 Biogen, Inc. Therapies for chronic renal failure using one or more integrin antagonists
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2002356180A1 (en) 2001-08-06 2003-03-10 The Regents Of The University Of California Methods for inhibiting angiogenesis
MXPA06008746A (es) * 2004-02-06 2007-01-23 Elan Pharm Inc Metodos y composiciones para tratamiento de tumores y enfermedad metastatica.
WO2007092471A2 (en) * 2006-02-03 2007-08-16 The Regents Of The University Of California Methods for inhibition of lymphangiogenesis and tumor metastasis
EP3042668B1 (en) * 2006-06-07 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
SG10201605629VA (en) * 2008-01-03 2016-08-30 Scripps Research Inst Antibody targeting through a modular recognition domain
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
KR101238061B1 (ko) * 2009-03-31 2013-02-27 한화케미칼 주식회사 Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물
PT3202789T (pt) * 2010-04-16 2020-06-16 Biogen Ma Inc Anticorpos anti-vla-4
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
EP2727937A4 (en) * 2011-06-30 2015-03-18 Immuno Biological Lab Co Ltd SOLUBLE MUTANT OF INEGRINE ALPHA-4
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
CN103215223B (zh) * 2013-03-18 2014-10-29 中国人民解放军第四军医大学 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法
CN103838980A (zh) * 2014-03-27 2014-06-04 山东大学 对多发性骨髓瘤骨病治疗方法的疗效进行模拟评测的方法
CN105688185B (zh) * 2016-03-13 2019-03-19 浙江药苑生物科技有限公司 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2017205560A1 (en) * 2016-05-27 2017-11-30 Albert Einstein College Of Medicine, Inc. Methods for treating cancer by targeting vcam1 and maea
US11560433B2 (en) 2016-05-27 2023-01-24 Albert Einstein College Of Medicine Methods of treatment by targeting VCAM1 and MAEA

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5217870A (en) 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5260277A (en) 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
DK0626861T4 (da) 1992-01-13 2004-08-16 Biogen Inc Behandling af astma.
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
EP0625912B1 (en) 1992-02-12 1997-04-16 Biogen, Inc. Treatment for inflammatory bowel disease
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DE69309487T2 (de) 1992-11-13 1997-10-23 Univ Washington Peripheralisierung hämatopoietischer stammzellen
WO1994015958A2 (en) 1993-01-08 1994-07-21 Tanabe Seiyaku Co., Ltd. Peptide inhibitors of cell adhesion
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
ES2114183T5 (es) 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
ES2270425T3 (es) * 1994-01-25 2007-04-01 Elan Pharmaceuticals, Inc. Anticuerpos humanizados contra la molecula de adhesion leucocitaria vla-4.
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US5885786A (en) 1996-04-19 1999-03-23 John Wayne Cancer Institute Methods for screening of substances for inhibition of multidrug resistance
PT923941E (pt) 1996-06-27 2006-09-29 Chugai Pharmaceutical Co Ltd Medicamentos para mieloma a serem utilizados com agentes antitumorais de mostarda nitrogenada
NZ509199A (en) * 1998-05-28 2003-10-31 Biogen Inc A VLA-4 inhibitor: oMePUPA-V
US9501219B2 (en) 2012-01-25 2016-11-22 Oracle International Corporation 2D line data cursor
US9713013B2 (en) 2013-03-15 2017-07-18 Elwha Llc Protocols for providing wireless communications connectivity maps
US9400266B2 (en) 2013-03-14 2016-07-26 Rosemount Analytical Inc. Gas chromatograph with improved operation
US9104862B2 (en) 2013-04-01 2015-08-11 Uniquesoft, Llc Secure computing device using new software versions

Also Published As

Publication number Publication date
SK287601B6 (sk) 2011-03-04
HUP0103630A3 (en) 2004-03-01
KR100628818B1 (ko) 2006-09-27
NO20011244D0 (no) 2001-03-12
EE05558B1 (et) 2012-08-15
IS5856A (is) 2001-02-23
CZ2001916A3 (cs) 2001-08-15
NO20011283D0 (no) 2001-03-14
CA2343579C (en) 2012-05-29
EP2065050A1 (en) 2009-06-03
CZ302997B6 (cs) 2012-02-15
CN1236815C (zh) 2006-01-18
CA2343579A1 (en) 2000-03-23
SI1113810T1 (sl) 2009-04-30
CY1109413T1 (el) 2014-08-13
ZA200102032B (en) 2002-11-07
EP1113810A2 (en) 2001-07-11
EA004270B1 (ru) 2004-02-26
PL347128A1 (en) 2002-03-25
AU6248699A (en) 2000-04-03
NO20011244L (no) 2001-05-14
KR20010085793A (ko) 2001-09-07
DK1113810T3 (da) 2009-04-06
BR9913705A (pt) 2001-06-05
NO327855B1 (no) 2009-10-05
HK1038313A1 (en) 2002-03-15
IL197686A0 (en) 2011-07-31
WO2000015247A3 (en) 2000-05-25
WO2000015247A8 (en) 2009-12-23
EE200100146A (et) 2002-06-17
DE69940206D1 (de) 2009-02-12
NZ511062A (en) 2003-04-29
HUP0103630A2 (hu) 2002-01-28
ES2319831T3 (es) 2009-05-12
CN1321091A (zh) 2001-11-07
WO2000015247A2 (en) 2000-03-23
SK6052001A3 (en) 2001-12-03
JP5378303B2 (ja) 2013-12-25
EA200100362A1 (ru) 2001-12-24
US20020022028A1 (en) 2002-02-21
US7211252B2 (en) 2007-05-01
JP2010235620A (ja) 2010-10-21
JP2013241441A (ja) 2013-12-05
PL203114B1 (pl) 2009-08-31
ATE418999T1 (de) 2009-01-15
AU757873B2 (en) 2003-03-06
TR200100734T2 (tr) 2001-07-23
HU229038B1 (hu) 2013-07-29
PT1113810E (pt) 2009-03-10
JP2002524529A (ja) 2002-08-06
EP1113810B1 (en) 2008-12-31
IS2631B (is) 2010-06-15

Similar Documents

Publication Publication Date Title
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
MY133996A (en) Compounds for the treatment of ischemia
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
DE69728782D1 (de) Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
ATE271393T1 (de) Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern
HUP9904567A3 (en) Use of azo, thioalkyl, thiocarbonyl derivatives substituted by fused heterocycles and/or phenyl group for the preparation of pharmaceutical compositions stimulating bone growth
IT1303790B1 (it) "apparecchiatura impiantabile di rilevazione elettromiograficainterno-esterno, in particolare per lo studio in vivo dell'attivita'
DE69924715D1 (de) Verwendung von angiotensin analogen zur herstellung eines arzneimittels zur steigerung des ueberlebens der weissen blutzellen und mobilisierung von haematopoietischen stammzellen nach einer chemotherapeutischen behandlung
YU13301A (sh) Muskarinski agonisti i antagonisti
EP1080724A4 (en) COMPOSITIONS FOR REDUCING MTP ACTIVITY
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
EP2236619A3 (en) BCL2L12 polypeptide activators and inhibitors
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
NZ510970A (en) The polycythaemia rubra vera gene and the use thereof
HUP9802048A3 (en) Synergetic compositions for inhibiting growth of tumors and methastases, and pharmaceutical compositions containing them
ZA9710452B (en) Compositions and methods for the preservation of living tissues.
IT1285551B1 (it) Composizione e procedimento per la sterilizzazione di substrati di coltura
IL120291A0 (en) Anti proliferative compositions obtained from plant cell or tissue culture

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees